Mitsubishi UFJ Trust & Banking Corp lessened its stake in Pfizer Inc. (NYSE:PFE) by 5.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,042,513 shares of the biopharmaceutical company’s stock after selling 357,860 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.11% of Pfizer worth $197,590,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in PFE. Hudson Bay Capital Management LP boosted its position in shares of Pfizer by 2.2% during the 2nd quarter. Hudson Bay Capital Management LP now owns 230,000 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 5,000 shares in the last quarter. Argus Investors Counsel Inc. boosted its holdings in Pfizer by 5.3% during the second quarter. Argus Investors Counsel Inc. now owns 108,480 shares of the biopharmaceutical company’s stock worth $3,547,000 after buying an additional 5,500 shares in the last quarter. AE Wealth Management LLC boosted its holdings in Pfizer by 35.0% during the second quarter. AE Wealth Management LLC now owns 376,967 shares of the biopharmaceutical company’s stock worth $12,327,000 after buying an additional 97,799 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Pfizer by 21.2% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 15,704 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,744 shares during the last quarter. Finally, Bank of Nova Scotia Trust Co. increased its holdings in shares of Pfizer by 6.1% in the second quarter. Bank of Nova Scotia Trust Co. now owns 80,342 shares of the biopharmaceutical company’s stock valued at $2,627,000 after buying an additional 4,591 shares in the last quarter. 69.08% of the stock is currently owned by hedge funds and other institutional investors.
PFE has been the topic of a number of recent research reports. TheStreet upgraded Pfizer from a “c+” rating to a “b” rating in a report on Monday, June 1st. Morgan Stanley increased their price target on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. ValuEngine downgraded Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. Royal Bank of Canada set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, September 9th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, June 1st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $39.61.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The firm had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 31st were issued a dividend of $0.38 per share. The ex-dividend date of this dividend was Thursday, July 30th. This represents a $1.52 annualized dividend and a dividend yield of 4.13%. Pfizer’s dividend payout ratio is 51.53%.
In other news, Director Ronald E. Blaylock acquired 13,000 shares of Pfizer stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at $154,200. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.08% of the stock is currently owned by company insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: What does EPS mean?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.